Drug modelling has become an essential tool in the drug design process. Software based drug discovery and development methods are playing key role in the development of novel drugs. Software based methods such as molecular modelling, structure-based drug design, structure-based virtual screening, ligand interaction and molecular dynamics are considered to be powerful tool for investigation of pharmacokinetic and pharmacodynamic properties of drugs. These methods are fast, accurate, and provide valuable insights of experimental findings and mechanisms of action. In addition, appropriate implementation of these techniques may help in reducing cost of drug designing and development.
Market Overview and Dynamics
TheEurope drug modelling software market is expected to reach US$ 3,215.94 million by 2027 from US$ 1,826.99 million in 2019. The market is anticipated to grow at a CAGR of 7.6% during 2019–2027. The increasing adoption of in-silico modelling tools in drug discovery, and increasing economic burden of drug discovery are the major factors expected to boost the growth of the drug modelling software market in Europe. However, the market is likely to get impacted by the risk factor such as lack of data standardization during the forecast period.
Key Market Segments
In terms of product type, the software segment accounted for the largest share of the Europe drug modelling software market in 2019. In terms of application, drug discovery and development segment accounted for the largest share of the Europe drug modelling software market in 2019.
Major Sources and Companies Listed
Several major primary and secondary sources associated with the Europe drug modelling software market report are the European Federation of Pharmaceutical Industries and Associations (EFPIA), European Medicines Agency (EMA), and others.
Reasons to buy report
It provides understanding of the Europe, drug modelling software market landscape and identifies drug modelling software market segments that are most likely to guarantee a strong return.
It guides stay ahead of the race by comprehending the ever-changing competitive landscape for the Europe drug modelling software market.
It helps efficiently plan merger and acquisition, and partnership deals in the drug modelling software market by identifying market segments with the most promising probable sales
It facilitates knowledgeable business decision-making through perceptive and comprehensive analysis of drug modelling software market performance of various segments pertaining to the Europe drug modelling software market.
It provides drug modelling software market revenue forecast of the market based on various segments for the period from 2019 to 2027.
EUROPE DRUG MODELLING SOFTWARE MARKET SEGMENTATION
By Product Type
Database
Software
Others
By Application
Drug Discovery and Development
Computational Physiological Medicine
Disease Modeling
Medical Imaging
Predictive Analysis of Drug Targets
Simulation Software
Cellular Simulation
Others
By Country
Germany
France
United Kingdom
Italy
Spain
Company Profiles
Crown Bioscience Inc (JSR life science)
Genedata AG
Biognos AB
Dassault Systèmes
Acellera
Europe Drug Modelling Software Market Strategic Insights
Get more information on this report
Europe Drug Modelling Software Market Segmentation Analysis
Europe Drug Modelling Software Market Report Highlights
Europe Drug Modelling Software Report Scope
Report Attribute
Details
Market size in 2019
US$ 1,826.99 Million
Market Size by 2027
US$ 3,215.94 Million
CAGR (2019 - 2027)
7.6%
Historical Data
2017-2018
Forecast period
2020-2027
Segments Covered
By Product Type
Database
Software
By Application
Drug Discovery and Development
Computational Physiological Medicine
Disease Modelling
Medical Imaging
Predictive Analysis of Drug Targets
Simulation Software
Cellular Simulation
Regions and Countries Covered
Europe
UK
Germany
France
Russia
Italy
Rest of Europe
Market leaders and key company profiles
Crown Bioscience Inc (JSR life science)
Genedata AG
Biognos AB
Dassault Systèmes
Acellera
Get more information on this report
Europe Drug Modelling Software Market Country and Regional Insights
Get more information on this report
Identical Market Reports with other Region/Countries
How big is the Europe Drug Modelling Software Market?
The Europe Drug Modelling Software Market is valued at US$ 1,826.99 Million in 2019, it is projected to reach US$ 3,215.94 Million by 2027.
What is the CAGR for Europe Drug Modelling Software Market by (2019 - 2027)?
As per our report Europe Drug Modelling Software Market, the market size is valued at US$ 1,826.99 Million in 2019, projecting it to reach US$ 3,215.94 Million by 2027. This translates to a CAGR of approximately 7.6% during the forecast period.
What segments are covered in this report?
The Europe Drug Modelling Software Market report typically cover these key segments-
Product Type (Database, Software)
Application (Drug Discovery and Development, Computational Physiological Medicine, Disease Modelling, Medical Imaging, Predictive Analysis of Drug Targets, Simulation Software, Cellular Simulation)
What is the historic period, base year, and forecast period taken for Europe Drug Modelling Software Market?
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Drug Modelling Software Market report:
Historic Period : 2017-2018
Base Year : 2019
Forecast Period : 2020-2027
Who are the major players in Europe Drug Modelling Software Market?
The Europe Drug Modelling Software Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
Crown Bioscience Inc (JSR life science)
Genedata AG
Biognos AB
Dassault Systèmes
Acellera
Who should buy this report?
The Europe Drug Modelling Software Market report is valuable for diverse stakeholders, including:
Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.
Essentially, anyone involved in or considering involvement in the Europe Drug Modelling Software Market value chain can benefit from the information contained in a comprehensive market report.
Get Free Sample For Europe Drug Modelling Software Market
